Dr. med. Dieter A. Wolf

1995
Doktortitel, Abteilung für Physiologische Chemie, Ludwig-Maximilians-Universität München

1992
Staatsexamen in Medizin, Ludwig-Maximilians-Universität München

seit 2023
Full Professor, Westlake Laboratory of Life Sciences and Biomedicine, Westlake University, Hangzhou, China

seit 2021

Arbeitsgruppenleiter, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technische Universität München

2020 – 2022
Gastprofessor, School of Pharmaceutical Sciences, Xiamen University, China

seit 2019
Arzt in Weiterbildung zum Facharzt für Humangenetik, Medizinisch Genetisches Zentrum München (MGZ)

2015 – 2019

Distinguished Professor, School of Pharmaceutical Sciences, Xiamen University, China

2007 – 2019
Professor, Burnham Institute, La Jolla, USA

1998 – 2007
Assistant/Associate Professor, Harvard School of Public Health

1994 – 1998
Postdoc, Stanford University School of Medicine und Harvard Medical School

1992 – 1994
Arzt im Praktikum, Klinik für Dermatologie, Ludwig-Maximilians-Universität München &
Forschungskollaboration am Institut für Klinische Molekularbiologie und Tumorgenetik, Helmholtz-Zentrum München

1988 – 1992
Promotion, Abteilung für Physiologische Chemie, Ludwig-Maximilians-Universität München
Androgenregulation der proliferationsassoziierten und gewebespezifischen Genexpression in humanen Prostatakarzinomzellen Mentor: Prof. Dr. Wolfram Hörz; Summa cum laude

• Jain S, Hu C, Kluza J, Ke W, Bleilevels A, Tian G, Giurgiu M, Campos AR, Charbono A, Stickeler E, Maurer J, Holinski-Feder E, Vaisburg A, Bureik M, Luo G, Marchetti P, Cheng Y, Wolf DA. Targeting cancer metabolism through a ubiquinone uncompetitive inhibitor of mitochondrial complex I, (2022) Cell Chemical Biology, 29, 436-450.e15, 10.1016/j.chembiol.2021.11.002
• Tian G, Hu Cheng, Yun Y, Yang W, Dubiel W, Cheng Y, Wolf DA. Dual roles of HSP70 chaperone HSPA1 in promoting quality control of nascent and newly synthesized proteins. (2021) EMBO J., e106183, 10.15252/embj.2020106183
• Wang J, Dubiel D, Wu Y, Cheng Y, Wolf DA*, Dubiel W*. CSN7B defines a variant COP9 signalosome complex with distinct function in DNA damage response. (2021) Cell Reports, 34: 108662, 10.1016/j.celrep.2020.108662 * Co-corresponding authors
• Lin Y, Li F, Huang L, Polte C, Duan H, Fan J, Sun L, Xing X, Tian G, Cheng Y, Ignatova Z, Yang X, Wolf DA. eIF3 associates with 80S ribosomes to promote translation elongation, mitochondrial homeostasis, and muscle health. (2020) Molecular Cell 79, 1-13, 10.1016/j.molcel.2020.06.003
• Shah M, Su D, Scheliga JS, Pluskal T, Boronat S, Shah M, Motamedchaboki K, Campos AR, Qi F, Yanagida M, Wolf DA. A transcript-specific eIF3 complex mediates global translational control of energy metabolism (2016), Cell Reports 16:1891-1902, 10.1016/j.celrep.2016.07.006
• Wu S, Zhu W, Nahn T, Toth J, Petroski MD, Wolf DA. CAND1 controls in vivo dynamics of the Cullin 1-RING ubiquitin ligase repertoire (2013), Nature Communications, 4:1642, 10.1038/ncomms2636
• Sha Z, Brill LM, Cabrera R, Kleifeld O, Glickman MH, Chang EC, Wolf DA. The eIF3 interactome reveals a supercomplex linking protein synthesis and degradation machineries (2009), Molecular Cell, 36:141-152, 10.1016/j.molcel.2009.09.026
• Schmidt MW, McQuary PR, Wee S, Hofmann K, Wolf DA. F-box-directed CRL complex assembly and regulation by the CSN and CAND1 (2009), Molecular Cell, 35:586-597, 10.1016/j.molcel.2009.07.024
• Wee S, Geyer R, Toda T, Wolf DA. CSN facilitates cullin/Ring ubiquitin ligase functions by counteracting autocatalytic adapter instability (2005), Nature Cell Biology 7:387-391, doi.org/10.1038/ncb1241
• Geyer R, Wee S, Anderson S, Yates J III, Wolf DA. BTB/POZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. (2003) Molecular Cell 12:783-790, doi.org/10.1016/S1097-2765(03)00341-1